期刊文献+

Inhibition of corneal neovascularization by topical application of nintedanib in rabbit models 被引量:2

下载PDF
导出
摘要 AIM:To evaluate the potential efficacy and mechanisms of nintedanib in corneal neovascularization(NV)in rabbit models.METHODS:Corneal NV was induced using 1 mol/L Na OH.Rabbits(n=21)were randomized to 3 groups:Group 1 were treated with 0.9%NaCl,Group 2 with Avastin(5 mg/mL),and Group 3 with nintedanib(1 mg/mL).All treatments star ted 1 d af ter alkaline burns and were topically performed 3 times a day for 2 wk.Photographs were taken on a slit lamp microscope on day 7 and 14.The NV area,the length of the vascularization and angiogenesis index(AI)were used to evaluate the corneal NV.On day 14,the immunohistochemical(IHC)studies of the cornea were examined.Western blot was performed to test the expression levels of vascular endothelial growth factor(VEGF),Akt,p-Akt,P38,p-P38,MMP-2 and MMP-9.RESULTS:The corneal NV area,vessel length and AI in Group 3 were significantly lower than Group 2,with both being lower than Group 1.IHC staining showed that VEGF was significantly overexpressed in the epithelium and stroma of cornea following alkaline burns.In contrast,the level of VEGF was significantly suppressed in both Group 2 and Group 3.Western blot results further confirmed that,compared with Group 1,Group 3 had significantly reduced expressions of VEGF,Akt,p-Akt,p-P38,MMP-2,and MMP-9 in corneal tissues.Trends of lower levels of MMP-2,AKT,and p-AKT in Group 3 than Group 2 were identified.CONCLUSION:Nintedanib and Avastin can effectively inhibit corneal NV,with P38 MAPK and AKT signaling pathways being possibly involved.Nintedanib seems more effective than Avastin and has the potential to be a novel therapy for preventing corneal NV.
出处 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2021年第11期1666-1673,共8页 国际眼科杂志(英文版)
基金 Supported by the Natural Science Foundation of Tianjin City(No.2150000045)
  • 相关文献

参考文献2

二级参考文献23

  • 1Felix Bock,Yanyan K?nig,Friedrich Kruse,Martin Baier,Claus Cursiefen.Bevacizumab (Avastin) eye drops inhibit corneal neovascularization[J]. Graefe’s Archive for Clinical and Experimental Ophthalmology . 2008 (2) 被引量:2
  • 2Chang J H,Gabison E E,Kato T,et al.Corneal neovascularization. Current Opinion in Ophthalmology . 2001 被引量:5
  • 3Bock F,Onderka J,Dietrich T Bachmann B,Kruse FE,Paschke M,Zahn G,Cursiefen C.Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Investigative Ophthalmology . 2007 被引量:3
  • 4Rosenfeld PJ,Brown DM,Heier JS,Boyer DS,Kaiser PK,Chung CY,Kim RY.Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, The . 2006 被引量:7
  • 5Manzano RP,Peyman GA,Khan P,Carvounis PE,Kivilcim M,Ren M,Lake JC,Chevez-Barrios P.Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). British Journal of Ophthalmology . 2007 被引量:1
  • 6Dana,M-R,Schaumberg,DA,Kowal,BO,Goren,MB,Rapuano,CJ,Laibson,PR,Cohen,EJ.Corneal vascularization after penetrating keratoplasty. Cornea . 1995 被引量:1
  • 7Luthra S,Narayanan R,Marques LE,Chwa M,Kim DW,Dong J,Seigel GM,Neekhra A,Gramajo AL,Brown DJ,Kenney MC,Kuppermann BD.Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina . 2006 被引量:1
  • 8Philipp W,Speicher L,Humpel C.Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investigative Ophthalmology . 2000 被引量:1
  • 9FERRARA N,HILLAN K J,NOVOTNY W.Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications . 2005 被引量:1
  • 10G Fuh,P Wu,WC Liang,M Ultsch,CV Lee,B Moffat,C Wiesmann.Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. Journal of Biological Chemistry . 2006 被引量:1

共引文献10

同被引文献19

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部